410 related articles for article (PubMed ID: 27545110)
1. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Ueberberg S; Jütte H; Uhl W; Schmidt W; Nauck M; Montanya E; Tannapfel A; Meier J
Diabetes Obes Metab; 2016 Dec; 18(12):1253-1262. PubMed ID: 27545110
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
3. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
[TBL] [Abstract][Full Text] [Related]
4. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
5. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
[TBL] [Abstract][Full Text] [Related]
6. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
7. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S5-9. PubMed ID: 20824239
[TBL] [Abstract][Full Text] [Related]
9. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
10. Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository.
Bonnet-Serrano F; Diedisheim M; Mallone R; Larger E
PLoS One; 2018; 13(1):e0191528. PubMed ID: 29352311
[TBL] [Abstract][Full Text] [Related]
11. [New hypoglycemic agents in type 2 diabetes].
Guerci B; Halter C
Rev Prat; 2010 Apr; 60(4):495-503. PubMed ID: 20465123
[TBL] [Abstract][Full Text] [Related]
12. Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
Kakimoto T; Kimata H; Iwasaki S; Fukunari A; Utsumi H
J Endocrinol; 2013 Jan; 216(1):13-20. PubMed ID: 23092878
[TBL] [Abstract][Full Text] [Related]
13. Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.
Augstein P; Naselli G; Loudovaris T; Hawthorne WJ; Campbell P; Bandala-Sanchez E; Rogers K; Heinke P; Thomas HE; Kay TW; Harrison LC
Diabetes Res Clin Pract; 2015 Dec; 110(3):291-300. PubMed ID: 26515908
[TBL] [Abstract][Full Text] [Related]
14. Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells.
Kim MJ; Choi OK; Chae KS; Lee H; Chung SS; Ham DS; Kim JW; Yoon KH; Park KS; Jung HS
Islets; 2015; 7(5):e1129096. PubMed ID: 26744903
[TBL] [Abstract][Full Text] [Related]
15. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
16. Dysfunction of the pancreas in healthy smoking persons and patients with chronic pancreatitis.
Milnerowicz H; Sliwinska-Mosson M; Rabczyński J; Nowak M; Milnerowicz S
Pancreas; 2007 Jan; 34(1):46-54. PubMed ID: 17198182
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
19. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.
Busch SJ; Hoffmann P; Sahota P; Johnson R; Kothny W; Meyer F; Foley JE
Diabetes Obes Metab; 2013 Jan; 15(1):72-6. PubMed ID: 22882290
[TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome influences the response to incretin-based therapies.
Fadini GP; de Kreutzenberg SV; Gjini R; Avogaro A
Acta Diabetol; 2011 Sep; 48(3):219-25. PubMed ID: 21574000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
